Why the study?
The diagnosis and management of heart failure are continually evolving, warranting an overview of emerging diagnostic and predictive methodologies.
Integrating novel diagnostic tools like emerging biomarkers, MRI, lung ultrasound, and AI can enhance early detection, risk stratification, and individualized management of heart failure.
The diagnosis and management of heart failure (HF) are continually evolving. Emerging biomarkers provide insights into the pathophysiology of HF and have recognized prognostic and diagnostic value. Additionally, the relationship between HF and the gut microbiota and their metabolites has been increasingly investigated, showing that dysbiosis can exacerbate cardiac dysfunction through systemic inflammation and metabolic disturbances. The role of magnetic resonance imaging in the early diagnosis of HF is discussed, showcasing its ability to provide detailed assessments of cardiac structure, function, and myocardial tissue. Furthermore, lung ultrasound is highlighted as an effective, non-invasive tool for evaluating pulmonary congestion in acute HF scenarios, offering real-time insights to guide clinical decision-making. Lastly, the potential applications of artificial intelligence in predicting outcomes in HF are addressed, demonstrating how artificial intelligence-driven models can enhance risk stratification and individualized management. This review underscores the significance of integrating these novel diagnostic and predictive methodologies to improve patient care in the management of HF.
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: